SARS-CoV-2 Mpro-IN-17

SARS-CoV-2 Mpro-IN-17

• UNSPSC Description: SARS-CoV-2 Mpro-IN-17 (compound S5-28) is an orally active and noncovalent SARS-CoV-2 Mpro inhibitor with the EC50 of 1.35 μM. SARS-CoV-2 Mpro-IN-17 can be used for study of COVID-19[1].
• Target Antigen: SARS-CoV
• Type: Reference compound
• Related Pathways: Anti-infection
• Applications: COVID-19-anti-virus
• Field of Research: Infection
• Assay Protocol: https://www.medchemexpress.com/sars-cov-2-mpro-in-17.html
• Smiles: O=C1N(CCCN)C2=CC=C(C=C2/C1=C3C(N(C)C4=C\3C=CC=C4)=O)Br.Cl
• Molecular Weight: 448.74
• References & Citations: [1]Gao Q, et al. Discovery of meisoindigo derivatives as noncovalent and orally available Mpro inhibitors: their therapeutic implications in the treatment of COVID-19. Eur J Med Chem. 2024;273:116498.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported